NCT07654972
A Study of LY4174794 in Participants With Obesity or Overweight Who Are Otherwise Healthy
Recruiting
PHASE1Ages 18–65InterventionalBasic scienceEli Lilly and Company
~108 participants
Updated 2026-07-16 on ClinicalTrials.gov
What's tested:LY4174794Placebo
At a glance
Recruiting sites
1 of 3 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration
Measured over Baseline through end of the Follow-up (Week 25)
+1 more outcome measured
Conditions
Where it's being run
3 sites across 3 statesTexas1
Utah1
Singapore1
Study leadership
- Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company
Who to contact
Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Eligibility criteria
Inclusion
Are overtly healthy with no comorbidities related to body mass index (BMI), such as type 2 diabetes mellitus or unstable cardiovascular disease
Are overweight with a BMI of ≥27 kilogram per meter square (kg/m²), or have obesity with a BMI of ≥30 kg/ m²
Have had a self-reported stable weight for 3 months prior to screening
Exclusion
Have a history or presence of cardiovascular, respiratory, hepatic, renal, GI, endocrine, hematological, or neurological disorders capable of significantly altering the absorption, metabolism, or elimination of drugs, or of constituting a risk when taking the study intervention, or of interfering with the interpretation of data
Is an individual of childbearing potential (IOCBP)
What this trial measures
- Part A and C: Number of Participants with One or More Treatment Emergent Adverse Events (TEAEs) and Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug AdministrationBaseline through end of the Follow-up (Week 25)
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.
- Part B: Number of Participants with One or More TEAEs and SAEs Considered by the Investigator to be Related to Study Drug AdministrationBaseline through end of the Follow-up (Week 39)
A summary of TEAEs and SAEs, regardless of causality, will be reported in the Reported Adverse Events module.